A phase II study of Tomudex alternated with methotrexate, 5- fluorouracil, leucovorin in first-line chemotherapy of metastatic colorectal cancer

Annals of Oncology

Volumn 10, Issue 8, 1999, Pages 985-987

  Cascinu, S ^a   Silva, R R ^b   Labianca, R ^c   Barni, S ^d   Mattioli, R ^h   Martignoni, G ^e   Frontini, L ^f   Gasparini, G ^g   Catalano, V ^a   Baldelli, A M ^a   Giuliodori, L ^b   Agostinelli, R ^a   Catalano, G ^a  

^a Azienda Ospedaliera Osp S S   (Italy)

^b Ospedale Profili   (Italy)

^c OSPEDALI RIUNITI   (Italy)

^d SAN GERARDO HOSPITAL   (Italy)

^e SAN CARLO BORROMEO HOSPITAL   (Italy)

^f SAN PAOLO HOSPITAL   (Italy)

^g BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^h NONE

Author keywords

Alternating regimens; Colorectal cancer; Methotrexate 5 fluorouracil combination; Tomudex

Indexed keywords

FLUOROURACIL; FOLINIC ACID; METHOTREXATE; RALTITREXED; SODIUM CHLORIDE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DRUG EFFICACY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER METASTASIS; LIVER TOXICITY; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; METASTASIS; MULTICENTER STUDY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT PLANNING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; LYMPHATIC METASTASIS; MALE; METHOTREXATE; MIDDLE AGED; PROGNOSIS; QUINAZOLINES; SURVIVAL RATE; THIOPHENES; TREATMENT OUTCOME;

EID: 0032881521     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008373817826     Document Type: Article

References (11)

1. Seymour MT. Colorectal cancer: Treatment of advanced disease. Cancer Treat Rev 1998; 24: 119-31.
2. Tuoroutoglu N, Pazdur R. Thymidilate synthase inhibitors. Clin Cancer Res 1996; 2: 227-43.
3. Sobrero AF. The potential role of Tomudex in the treatment of advanced colorectal cancer. Tumori 1997; 83: 576-80.
4. Johnstone P, Behan K, Allegra C. Fluorouracil: Active in ZD1694 (Tomudex) resistant cell lines with markedly elevated thymidilate synthase levels. J Natl Cancer Inst 1995; 87: 1558-9.
5. Sobrero AF, Aschele C, Gulgielmi AP et al. Schedule-selective biochemical modulation of 5-fluorouracil: A phase II study in advanced colorectal cancer. Clin Cancer Res 1995; 1: 955-60.
6. Miller AB, Hoodgstraten B, Staquet M et al. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
7. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1-10.
8. Sobrero AF, Aschele C, Bertino JR. Fluorouracil in colorectal cancer - a tale of two drugs: Implications for biochemical modulation. J Clin Oncol 1997; 368-81.
9. Sobrero AF, Aschele C, Guglielmi AP et al. Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells. J Natl Cancer Inst 1993; 85: 1937-44.
10. Sobrero AF, Frassineti GL, Giuliani R et al. Randomized comparison between sequential MTX/5-FU and schedule specific biochemical modulation in advanced colorectal cancer. Ann Oncol 1998; 9 (Suppl 4): 157.
11. Longo GSA, Izzo J, Chang YM et al. Pretreatment of colon carcinoma cells with tomudex enhances 5-fluorouracil cytotoxicity. Clin Cancer Res 1998; 4: 469-73.